Neuronetics, Inc. (NASDAQ:STIM) Director Glenn P. Muir Buys 25,000 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) Director Glenn P. Muir bought 25,000 shares of the stock in a transaction on Thursday, September 5th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $20,000.00. Following the acquisition, the director now directly owns 289,818 shares in the company, valued at $231,854.40. The transaction was disclosed in a filing with the SEC, which is available through this link.

Neuronetics Price Performance

NASDAQ:STIM opened at $0.78 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.58 and a debt-to-equity ratio of 2.38. The company has a 50-day moving average of $1.47 and a 200-day moving average of $2.58. Neuronetics, Inc. has a 52 week low of $0.66 and a 52 week high of $5.07.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The business had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. Neuronetics had a negative return on equity of 109.00% and a negative net margin of 45.06%. During the same quarter in the prior year, the business earned ($0.17) EPS. As a group, research analysts forecast that Neuronetics, Inc. will post -0.87 EPS for the current fiscal year.

Institutional Trading of Neuronetics

Several institutional investors have recently bought and sold shares of STIM. Worth Venture Partners LLC acquired a new position in Neuronetics during the fourth quarter worth $30,000. SG Americas Securities LLC acquired a new stake in shares of Neuronetics during the 1st quarter worth about $62,000. Legato Capital Management LLC acquired a new position in Neuronetics in the second quarter valued at about $44,000. FourWorld Capital Management LLC bought a new stake in Neuronetics during the first quarter worth about $171,000. Finally, Gabelli Funds LLC increased its holdings in shares of Neuronetics by 88.2% during the second quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock worth $86,000 after buying an additional 22,500 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. JMP Securities reduced their price objective on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 14th. Canaccord Genuity Group decreased their price target on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, William Blair reissued a “market perform” rating on shares of Neuronetics in a research report on Monday, August 12th.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.